Sign In
Buy OGN
$13.56
+0 (+0%)
At Close: Aug 04, 2026
Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights
07:00pm, Friday, 27'th Mar 2026
In the latest trading session, Organon (OGN) closed at $5.84, marking a -3.47% move from the previous day.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients.
Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026
07:30am, Tuesday, 24'th Mar 2026
VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") reports preliminary and unaudited financial results for its fourth quarter
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
05:22pm, Friday, 20'th Mar 2026
Sio initiated a new OGN position in the fourth quarter, buying up 3,421,765 shares. The quarter-end position value increased by $24.53 million as a result.
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
12:11pm, Friday, 20'th Mar 2026
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a po
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
07:00pm, Wednesday, 18'th Mar 2026
Organon (OGN) closed at $6.23 in the latest trading session, marking a -2.5% move from the prior day.
Orogen Royalties Announces Private Placement Update
06:45pm, Wednesday, 18'th Mar 2026
VANCOUVER, BC / ACCESS Newswire / March 18, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") announces that, further to its news release dated March 12, 2026, the Compa
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:01am, Tuesday, 17'th Mar 2026
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Orogen Royalties Announces Non-Brokered Private Placement of up to $10 Million
07:30am, Thursday, 12'th Mar 2026
VANCOUVER, BC / ACCESS Newswire / March 12, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce it intends to raise up to $10,000,000 by way of a no
STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (P
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis
02:01pm, Monday, 02'nd Mar 2026
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.
Orogen Royalties Creates a Royalty on the Ecru Gold Project in Nevada, USA
08:30am, Friday, 27'th Feb 2026
VANCOUVER, BC / ACCESS Newswire / February 27, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
07:30am, Monday, 23'rd Feb 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty
04:56am, Sunday, 22'nd Feb 2026
Organon reported a disappointing Q4, with revenue down 5% YoY and significant weakness in women's health. Shares are heavily oversold, but I maintain a Hold rating due to strategic uncertainty and lac
